CD3-CD56+ NK cells display an inflammatory profile in RR-MS patients

TAHRALI İ., KÜÇÜKSEZER U. C., AKDENİZ N., Altintas A., UYGUNOĞLU U., ÇETİN E., ...More

Immunology Letters, vol.216, pp.63-69, 2019 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 216
  • Publication Date: 2019
  • Doi Number: 10.1016/j.imlet.2019.10.006
  • Journal Name: Immunology Letters
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.63-69
  • Keywords: IL-22, Multiple sclerosis, Natural killer cells, NKG2A, NKG2D, NKp44
  • Istanbul Medipol University Affiliated: No

Abstract

Multiple Sclerosis (MS) is an immune-mediated and neurodegenerative disease of central nervous system. Relapsing-remitting (RR)-MS occurring with acute attacks and remissions, is the most common clinical type of MS. There are different strategies applied in first-line treatment of RR-MS patients such as interferon-beta (IFN-β) and glatiramer acetate. In this study, activating and inhibitory receptor expressions and interleukin (IL)-22 levels of NK cells were investigated in RR-MS patients with or without IFN-β therapy. Activating receptor expression and IL-22 levels of NK cells were increased in RR-MS patients under IFN-β therapy. Elevated NK cells with activating profile and increased IL-22 under IFN-β therapy suggest that IFN-β treatment might direct NK cells toward a pro-inflammatory status.